Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open‐label trial

R. F. Arakaki; T. C. Blevins; J. K. Wise; D. R. Liljenquist; H. H. Jiang; J. G. Jacobson; S. A. Martin; J. A. Jackson

doi:10.1111/dom.12242

Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open‐label trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12242 ◽

2013 ◽

Vol 16 (6) ◽

pp. 510-518 ◽

Cited By ~ 9

Author(s):

R. F. Arakaki ◽

T. C. Blevins ◽

J. K. Wise ◽

D. R. Liljenquist ◽

H. H. Jiang ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Insulin Lispro ◽

Open Label ◽

Once Daily ◽

Open Label Trial

Download Full-text

Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2011.01484.x ◽

2011 ◽

Vol 13 (12) ◽

pp. 1149-1157 ◽

Cited By ~ 10

Author(s):

V. Koivisto ◽

S. Cleall ◽

A. E. Pontiroli ◽

D. Giugliano

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Insulin Lispro ◽

Open Label ◽

Once Daily ◽

Open Label Trial ◽

Basal Bolus ◽

Diabetes Patients

Download Full-text

Postprandial renal haemodynamic effect of lixisenatide vs once‐daily insulin‐glulisine in patients with type 2 diabetes on insulin‐glargine: An 8‐week, randomised, open‐label trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12985 ◽

2017 ◽

Vol 19 (12) ◽

pp. 1669-1680 ◽

Cited By ~ 27

Author(s):

Lennart Tonneijck ◽

Marcel H. A. Muskiet ◽

Mark M. Smits ◽

Trynke Hoekstra ◽

Mark H. H. Kramer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Haemodynamic Effect ◽

Open Label ◽

Once Daily ◽

Daily Insulin ◽

Open Label Trial ◽

Insulin Glulisine

Download Full-text

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

The Lancet ◽

10.1016/s0140-6736(15)60936-9 ◽

2015 ◽

Vol 385 (9982) ◽

pp. 2057-2066 ◽

Cited By ~ 122

Author(s):

Lawrence Blonde ◽

Johan Jendle ◽

Jorge Gross ◽

Vincent Woo ◽

Honghua Jiang ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Insulin Lispro ◽

Open Label ◽

Phase 3 ◽

Prandial Insulin ◽

Open Label Phase

Download Full-text

Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus

Journal of Diabetes ◽

10.1111/1753-0407.12426 ◽

2016 ◽

Vol 9 (4) ◽

pp. 396-404 ◽

Cited By ~ 3

Author(s):

In-Kyung Jeong ◽

Choon Hee Chung ◽

Zhiguang Zhou ◽

Jeong Hee Han ◽

Ran Duan ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Insulin Glargine ◽

Insulin Lispro ◽

East Asian ◽

Once Daily ◽

Insulin Intensification ◽

Caucasian Patients

Download Full-text

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in J apanese patients with type 2 diabetes: a randomized, open‐label, phase III , non‐inferiority study

Diabetes Obesity and Metabolism ◽

10.1111/dom.12540 ◽

2015 ◽

Vol 17 (10) ◽

pp. 994-1002 ◽

Cited By ~ 50

Author(s):

E. Araki ◽

N. Inagaki ◽

Y. Tanizawa ◽

T. Oura ◽

M. Takeuchi ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Once Daily ◽

Daily Insulin ◽

Open Label Phase

Download Full-text

Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape)

Diabetes Obesity and Metabolism ◽

10.1111/dom.12528 ◽

2015 ◽

Vol 17 (12) ◽

pp. 1133-1141 ◽

Cited By ~ 23

Author(s):

J. Vora ◽

N. Cohen ◽

M. Evans ◽

A. Hockey ◽

J. Speight ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Insulin Aspart ◽

Basal Insulin ◽

Insulin Regimen ◽

Open Label ◽

Biphasic Insulin ◽

Open Label Trial ◽

Insulin Glulisine

Download Full-text

Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT

Current Medical Research and Opinion ◽

10.1185/03007990903354674 ◽

2009 ◽

Vol 25 (12) ◽

pp. 2887-2894 ◽

Cited By ~ 56

Author(s):

Krzysztof Strojek ◽

Wan M.W. Bebakar ◽

Duma T. Khutsoane ◽

Milica Pesic ◽

Alena Šmahelová ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Insulin Aspart ◽

Oral Drugs ◽

Open Label ◽

Once Daily ◽

Biphasic Insulin Aspart ◽

Biphasic Insulin ◽

Biphasic Insulin Aspart 30

Download Full-text

Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: A 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy

Clinical Therapeutics ◽

10.1016/j.clinthera.2004.12.015 ◽

2004 ◽

Vol 26 (12) ◽

pp. 2034-2044 ◽

Cited By ~ 123

Author(s):

James K. Malone ◽

Lisa F. Kerr ◽

Barbara N. Campaigne ◽

Richard A. Sachson ◽

John H. Holcombe

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Insulin Therapy ◽

Crossover Study ◽

Insulin Lispro ◽

Combined Therapy ◽

Open Label

Download Full-text

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(08)60485-7 ◽

2008 ◽

Vol 371 (9618) ◽

pp. 1073-1084 ◽

Cited By ~ 228

Author(s):

Reinhard G Bretzel ◽

Ulrike Nuber ◽

Wolfgang Landgraf ◽

David R Owens ◽

Clare Bradley ◽

...

Keyword(s):

Type 2 Diabetes ◽

Randomised Controlled Trial ◽

Insulin Glargine ◽

Insulin Lispro ◽

Controlled Trial ◽

Oral Hypoglycaemic Agents ◽

Once Daily ◽

Hypoglycaemic Agents ◽

Randomised Controlled

Download Full-text

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(17)30085-2 ◽

2017 ◽

Vol 5 (5) ◽

pp. 355-366 ◽

Cited By ~ 116

Author(s):

Vanita R Aroda ◽

Stephen C Bain ◽

Bertrand Cariou ◽

Milivoj Piletič ◽

Ludger Rose ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Efficacy And Safety ◽

Open Label ◽

Once Daily ◽

Daily Insulin ◽

Parallel Group

Download Full-text